美银证券发表报告表示，将百济神州(06160.HK) 评级由“中性”升至“买入”，目标价由125元升至193.23元。
该行指，由于Brukinsa(布鲁顿酪氨酸激酶(BTK)的小分子抑制剂)在美国的销售增长强劲，而上调其收入预测，从而整体上调公司今年至2027年的收入预测分别6%、11.8%及15.5%。该行亦因为公司的产品及项目组合扩张而调整了其研发和行政支出。该行指，公司为今年全年提供指引，收入增长落在29%至39%，并称经营收入及今年自经营活动的现金流产生为正面。(vc/w)(港股报价延迟最少十五分钟。沽空资料截至 2025-02-28 16:25。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.